Trevi Therapeutics (TRVI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on April 4. Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on the stock and has a $11.00 price target.
Faisal Khurshid’s rating is based on several key insights gained from a recent investor meeting with Trevi Therapeutics’ management. The company is advancing Haduvio, an oral therapy, for conditions like idiopathic pulmonary fibrosis (IPF) cough and refractory chronic cough (RCC). The upcoming data from the CORAL trial in IPF cough is highly anticipated, especially after the positive results from the Phase 2a RIVER trial in RCC. The management’s discussion highlighted lower discontinuation rates in the CORAL trial compared to previous studies, which is attributed to strategies that help patients manage side effects.
Furthermore, the management provided valuable insights into the competitive landscape, indicating that Haduvio could be a differentiated therapy in the market. They also discussed the trial’s design and statistical assumptions, which appear conservative but promising. The company’s strategic approach and the potential of Haduvio in addressing unmet needs in IPF cough and RCC contribute to the Buy rating, as the upcoming data could significantly impact the company’s trajectory.
According to TipRanks, Khurshid is a 5-star analyst with an average return of 26.5% and a 42.19% success rate. Khurshid covers the Healthcare sector, focusing on stocks such as Pliant Therapeutics, Trevi Therapeutics, and aTyr Pharma.